AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

NCTID	NCT06063850 (View at clinicaltrials.gov)
Description	This is a study of AMT-260 in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE). It is designed to investigate the Safety, Tolerability, and Efficacy of AMT-260 in Adults with MTLE Administered via Magnetic Resonance Imaging (MRI)-guided Convection-enhanced Delivery (CED). (Show More)
Indication	Temporal Lobe Epilepsy
Compound Name	AMT-260
Sponsor	uniQure France SAS
Funder Type	Industry
Status	Recruiting
Enrollment Count	12

Target Gene/Variant	MiGRIK2
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	MiRNA knockdown of mutant/aberrant gene
Route of Administration	Intraparenchymal
Drug Product Type	Viral vector
Target Tissue/Cell
Delivery System	Viral transduction
Vector Type	AAV9
Editor Type
Dose 1	Undisclosed low dose
Dose 2	Undisclosed high dose
Dose 3
Dose 4
Dose 5

No.of Trial Sites	2
Locations	United States

Has US IND	True
Recent Updates